⌘K
t
On 19 December 2024, Aptamer Group plc announced a new development contract with a rare disease biopharmaceutical company. This agreement is valued at up to £155,000 for the development of two Optimer binders for therapeutic monitoring. The contract also provides for Aptamer to receive a significant undisclosed IP transfer fee upon successful development and use of the Optimers in clinical trial monitoring.
| Date | 19 Dec 2024 |
| Time | 07:00:06 |
| Category | Corporate updates |
| ID | 6662Q |
19 December 2024
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
New Development Contract
Agreement worth up to £155,000 and potential for significant IP transfer fee payment upon success
Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces the signing of a new development contract with a rare disease biopharmaceutical company. The agreement, worth up to £155,000, focuses on developing two Optimer binders as critical reagents for therapeutic monitoring. Upon successful development, Aptamer could receive a significant undisclosed IP transfer fee for the use of the Optimers in clinical trial monitoring.
Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented: "This agreement further demonstrates our strategic model of leveraging fee-for-service revenue for the development of Optimer binders and potential licensing revenues.
With a healthy pipeline and increasing traction among both new and repeat customers, we are demonstrating our commercial strategy. These advancements align with our broader vision of driving shareholder value by pairing fee-for-service income with scalable licensing opportunities. We remain focused on delivering on our growth objectives and look forward to sharing updates on our continued progress."
- Ends -
For further information, please contact:
|
Aptamer Group plc Arron Tolley, Chief Executive Officer |
+44 (0) 1904 217 404 |
|
SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Adam Dawes |
+44 (0) 20 3368 3550 |
|
Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker |
+44 (0) 20 3657 0050 |
|
Northstar Communications Limited - Investor Relations Sarah Hollins |
+44 (0) 113 730 3896 |
About Aptamer Group plc
Aptamer Group is a leading global developer of aptamer-based ligands that help scientists remove the limits to discovery and innovation. Leveraging a proprietary discovery and development platform, Aptamer delivers custom affinity ligands, supported with a complete suite of characterisation and validatory assays that enhance the translation of its binders and optimise scientific outcomes for customers.
Aptamer's cutting-edge technology spans healthcare, research, personal care, and industrial processes, delivering new affinity solutions for novel targets, advanced diagnostics, and precision therapies. By working with industry leaders in pharmaceutical, biotechnology, personal health, academic, and clinical research sectors, Aptamer is accelerating science through the custom development of tools and therapies.
To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/